Lazari Capital Management Inc. acquired a new position in shares of Humacyte, Inc. (NASDAQ:HUMA – Free Report) in the second quarter, HoldingsChannel.com reports. Institutional investors and hedge funds own 44.71% of the company’s stock. Insiders sold a total of 4,482,090 shares of company stock valued at $7,466,382 over the last ninety days. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Monday, September 15th. According to MarketBeat, Humacyte currently has an average rating of “Moderate Buy” and an average price target of $9.29.